ReviewNature clinical practice. Nephrology2009
Sickle cell disease and the kidney.
Review in Nature clinical practice. Nephrology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.The Cochrane database of systematic reviews · 2021Pooled it
- Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.The Cochrane database of systematic reviews · 2015Pooled it
- Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.American journal of hematology · 2013Trial
- Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.Pediatric blood & cancer · 2012Trial
- The Unfinished Story of Sickle Cell Nephropathy: A Narrative Review of Knowledge Gaps and Research Imperatives.Journal of clinical medicine · 2026Review
- A Review of the Clinical Utility of Tubule-Specific Biomarkers in Sickle Cell Nephropathy.BioMed research international · 2026Review
- Genotype-dependent albuminuria in adult sickle cell disease in Kinshasa.Annals of hematology · 2025Article
- Article
- Prevalence and associated factors of glomerular hyperfiltration among adult stable sickle cells in Kinshasa, DR Congo.Renal failure · 2024Article
- End Organ Affection in Sickle Cell Disease.Cells · 2024Review
- Euvolemic automated transfusion to treat severe anemia in sickle cell disease patients at risk of circulatory overload.Transfusion · 2024Article
- Ultrasound Imaging in Subjects with Sickle Cell Disease: The Saudi Arabia Experiences.International journal of general medicine · 2023Article
- Risk factors associated with sickle cell retinopathy: findings from the Cooperative Study of Sickle Cell Disease.International journal of retina and vitreous · 2022Article
- Increasing nitric oxide bioavailability fails to improve collateral vessel formation in humanized sickle cell mice.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model.American journal of physiology. Cell physiology · 2022Review
- Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohorts.Kidney international supplements · 2022Review
- Acute kidney injury in hospitalized children with sickle cell anemia.BMC nephrology · 2022Article
- Prevalence and Factors Associated with Acute Kidney Injury in Sub-Saharan African Adults: A Review of the Current Literature.International journal of nephrology · 2022Review
- Pain in sickle cell disease: current and potential translational therapies.Translational research : the journal of laboratory and clinical medicine · 2021Review
- Outcomes of Kidney Transplant Recipients with Sickle Cell Disease: An Analysis of the 2000-2019 UNOS/OPTN Database.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The renal features of sickle cell disease (SCD) include some of the most common reasons for referral to nephrologists, such as hematuria, proteinuria, tubular disturbances and chronic kidney disease. Therapy of these conditions requires specialized knowledge of their distinct pathogenic mechanisms. Painless hematuria is usually benign--unless massive--and can be treated with hydration alone if renal medullary carcinoma has been ruled out. Tubular functional defects, which tend to reduce urinary concentrating capacity, generally require no specific treatment. Proteinuria might indicate the development of chronic sickle cell nephropathy, which can be treated effectively. Measurement of glomerular filtration rate in SCD is problematic, which makes identification and monitoring of chronic kidney disease difficult in patients with SCD. Although managing and predicting the outcomes of chronic kidney disease in the SCD setting is challenging, affected individuals do benefit from transplantation. This Review summarizes the presentation, processes, pathology, modifiers, diagnosis and treatment of the renal effects of SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.